6 results about "Transcript level" patented technology

This invention relates to oligonucleotide compositions and methods for using the same. [Solution] In particular, this disclosure provides designed oligonucleotides, compositions thereof and methods of use. In some embodiments, this disclosure provides techniques useful for reducing transcript levels. In some embodiments, this disclosure provides techniques useful for modulating transcript splicing. In some embodiments, the techniques provided can alter the splicing of dystrophin (DMD) transcripts. In some embodiments, this disclosure provides methods for treating diseases such as Duchenne muscular dystrophy and Becker muscular dystrophy.

This invention discloses the artificial synthesis of the disease-resistant gene NLP27 and its application, belonging to the field of plant genetic engineering technology. This invention selects a conserved 27-amino acid fragment from Verticillium dahliae NLP1, modifies its nucleotide sequence, and synthesizes the NLP27 gene, which is then overexpressed in potato plants through genetic transformation. Inoculation analysis shows that transgenic plants with the NLP27 gene exhibit high resistance to potato late blight and scab. Quantitative PCR analysis shows that excessively high NLP27 transcript levels significantly inhibit potato plant growth. After screening for expression levels and disease resistance, three transgenic lines with moderate NLP27 expression levels (such as PT1, PT6, and PT7) were obtained. These lines significantly enhanced resistance to potato late blight and scab without sacrificing yield.

The present disclosure relates to the technical field of cell culture. It provides a method that facilitates the selection of single cell clones or cell pools for the manufacture of antigen binding proteins having two to four different antibody chains. The method utilizes ddPCR to quantify the transcript level.

A cell-based screening system and method for identifying compounds that selectively modulate the expression of CAG repeat-containing RNA associated with spinocerebellar ataxias and related disorders. The system comprises a human HEK293T cell line engineered to co-express two reporter constructs: a CAG repeat-expanded polyglutamine-nanoluciferase fusion protein with at least 60 CAG repeats, and a control firefly luciferase with no CAG repeats. Each construct contains a unique probe-binding sequence downstream of the repeat region, enabling independent quantification via multiplex RT-qPCR with fluorescent probes, as well as dual luciferase assays. The cell line is optimized for high-throughput screening to identify therapeutic compounds that reduce pathogenic CAG repeat RNA levels while sparing control transcripts. The invention further encompasses methods for screening, validating, and identifying candidate therapeutics for CAG expansion disorders, including spinocerebellar ataxias and Huntington's disease.

The invention discloses siRNA (small interfering Ribonucleic Acid) for inhibiting the expression of a chicken RASGRP3 (Reduced Amplification of Sequence Growth Protein 3) gene and application of the siRNA, the siRNA comprises a positive-sense strand and an antisense strand, and is any one of RASGRP3-Anas-214, RASGRP3-Anas-846 and RASGRP3-Anas-1187. According to the specific siRNA aiming at the chicken RASGRP3 mRNA provided by the invention, in a chicken liver cancer cell line (LMH), after liposome-mediated transfection culture is performed for 48 hours, RT-qPCR is adopted to evaluate the transcript level, and a result shows that the relative expression quantity of the chicken RASGRP3 mRNA is remarkably reduced compared with that of negative control, and the repeatability is good. The polypeptide can be further used for inhibiting ALV-J replication, provides a new molecular intervention target for prevention and control of avian leukosis, and has important scientific research and potential economic values.

The present invention provides methods of using the RNA analysis to identify a cell type from which a midbody remnant (MBR) originated. The methods include isolating MBR, analyzing the RNA in the MBR to determine RNA transcript levels, and using the RNA transcript levels to identify a cell type from which the MBR originated. The method may be used to detect proliferative diseases including cancer by comparing RNA transcript levels to control levels.